Analyst Research Report Snapshot

Title:

WhanIn Pharmaceutical Co., Ltd.

Price:

$50.00

Provider:

MarketLine (a Datamonitor Company)

Date:

01 Jun 2012

Pages:

21

Type:

AcrobatPDF

Companies referenced:

016580.KS

Available for Immediate Download
Summary:

WhanIn Pharmaceutical Co., Ltd. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on WhanIn Pharmaceutical Co., Ltd. required for business and competitor intelligence needs - Intelligence on WhanIn Pharmaceutical Co., Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about WhanIn Pharmaceutical Co., Ltd., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: WhanIn Pharmaceutical (WhanIn) is a South Korean-based pharmaceutical company that develops, manufactures, markets, and sells therapeutic products. The company's therapeutic products include antidepressants, antipsychotics, anxiolytics and hypnotics, antiepileptics, ADHD agents, alcoholism treatment drugs, nootropics, antiparkinson drugs, antidementia drugs, gastrointestinal drugs, cardiovascular drugs, osteoporosis treatment drugs, immunostimulating agents, antiinflammatory analgesics and others, antibiotics, multi-vitamins, antihaemorrhoids, antidiabetic agents, respiratory drugs, antifungals, antihistamines, dermatologicals, drugs for prostate disorders, and antivirals. The company primarily operates in South Korea, where it is headquartered in Seoul, and employs around 410 people. The company recorded revenues of KRW105,687.1 million (approximately $91.9 million) in the fiscal year ended December 2010, an increase of 6.3% over 2009. The company's operating profit was KRW20,335.9 million (approximately $17.7 million) in fiscal 2010, an increase of 13.7% over 2009. Its net profit was KRW17,236.9 million (approximately $15 million) in fiscal 2010, an increase of 19.4% over 2009. Reasons to Purchase: - Gain understanding of WhanIn Pharmaceutical Co., Ltd. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess WhanIn Pharmaceutical Co., Ltd. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on WhanIn Pharmaceutical Co., Ltd. your competitors' business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.